WVE
Wave Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$3.17
+1.28%Oct 19, 2026, 12:30 UTC
Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.
Source:Oct 1, 2026, 11:30 UTC
The FDA provided feedback supporting a registrational pathway for Wave Life Sciences' WVE-006 RNA editing therapy in alpha-1 antitrypsin deficiency, following which Wave plans a single two-year registrational trial with a one-year interim analysis for potential accelerated approval.
Source:Sep 30, 2026, 11:30 UTC
GSK selected a siRNA program from Wave Life Sciences to transition to GSK for further development, triggering a milestone payment to Wave, with three additional collaboration programs advancing.
Source:Sep 23, 2026, 11:30 UTC
Wave Life Sciences initiated a Phase 2a combination trial of WVE-007 (GalNAc-siRNA) with tirzepatide for obesity.
Source:Sep 22, 2026, 11:30 UTC
Wave Life Sciences Ltd. appointed Dr. Monika Vnuk as Chief Business Officer.
Source:Aug 10, 2026, 12:30 UTC
Wave Life Sciences completed its redomiciliation from a Singapore company to a Delaware corporation via a scheme of arrangement under Singapore law.
Source:Jul 30, 2026, 00:00 UTC
Wave Life Sciences Ltd. reported financial results for the second quarter of 2026, with total revenue of $2.3 million and a net loss of $69.4 million.
Source:Jul 7, 2026, 20:15 UTC
Wave Life Sciences announced that it has obtained shareholder approval for its redomiciliation to the United States via a scheme of arrangement, which is subject to a Singapore Court hearing on July 14, 2026.
Source: